"David Nicholson’s leadership, experience, and passion for research have made him one of the world’s most respected pharmaceutical R&D executives - he's an extraordinarily talented business development, operating, and research executive," said Elizabeth Iorns Ph.D., founder and CEO of Science Exchange. "We are fortunate to add David to Science Exchange’s Board of Directors during this exciting phase of the company’s growth."

"David is a seasoned R&D leader who brings an exceptional track record spanning more than 40 years in the pharmaceutical industry," said Casper de Clercq, Science Exchange Board Member and Partner at Norwest Venture Partners. "His deep experience working in R&D across the U.S., UK, Germany and the Netherlands, and his unique understanding of the global clinical and regulatory environment, will be invaluable as Science Exchange continues its rapid international expansion.”

Dr. Nicholson joined Allergan (then Actavis) as Senior Vice President, Global Brands R&D in August 2014. Previously Dr. Nicholson held senior leadership roles in R&D including serving as the Head of R&D at Bayer CropScience; Executive Vice President of R&D at Organon; and Senior Vice President Licensing and Knowledge Management at Merck.

"I am thrilled to join the Science Exchange Board of Directors," said Dr. Nicholson. "I've been following the company for some time now and am a true believer in the transformative platform it has developed for R&D companies. I admire the work that Elizabeth, Dan, and the talented Science Exchange management team have done over the past few years to speed up the process of R&D outsourcing. I look forward to joining the team and helping them further transform the outsourced R&D industry."

Dr. Nicholson also serves on the Board of Directors of Actinium Pharmaceuticals. He earned a Ph.D. in Pharmacology from University of Wales and a BSc in Pharmacology from Manchester University.